TY - JOUR
T1 - Short report
T2 - Plasma based biomarkers detect radiation induced brain injury in cancer patients treated for brain metastasis: A pilot study
AU - Makranz, Chen
AU - Lubotzky, Asael
AU - Zemmour, Hai
AU - Shemer, Ruth
AU - Glaser, Benjamin
AU - Cohen, Jonathan
AU - Maoz, Myriam
AU - Sapir, Eli
AU - Wygoda, Marc
AU - Peretz, Tamar
AU - Weizman, Noam
AU - Feldman, Jon
AU - Abrams, Ross A.
AU - Lossos, Alexander
AU - Dor, Yuval
AU - Zick, Aviad
N1 - Publisher Copyright:
Copyright: © 2023 Makranz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2023/11
Y1 - 2023/11
N2 - Background Radiotherapy has an important role in the treatment of brain metastases but carries risk of short and/or long-term toxicity, termed radiation-induced brain injury (RBI). As the diagnosis of RBI is crucial for correct patient management, there is an unmet need for reliable biomarkers for RBI. The aim of this proof-of concept study is to determine the utility of brain-derived circulating free DNA (BncfDNA), identified by specific methylation patterns for neurons, astrocytes, and oligodendrocytes, as biomarkers brain injury induced by radiotherapy. Methods Twenty-four patients with brain metastases were monitored clinically and radiologically before, during and after brain radiotherapy, and blood for BncfDNA analysis (98 samples) was concurrently collected. Sixteen patients were treated with whole brain radiotherapy and eight patients with stereotactic radiosurgery. Results During follow-up nine RBI events were detected, and all correlated with significant increase in BncfDNA levels compared to baseline. Additionally, resolution of RBI correlated with a decrease in BncfDNA. Changes in BncfDNA were independent of tumor response. Conclusions Elevated BncfDNA levels reflects brain cell injury incurred by radiotherapy. further research is needed to establish BncfDNA as a novel plasma-based biomarker for brain injury induced by radiotherapy.
AB - Background Radiotherapy has an important role in the treatment of brain metastases but carries risk of short and/or long-term toxicity, termed radiation-induced brain injury (RBI). As the diagnosis of RBI is crucial for correct patient management, there is an unmet need for reliable biomarkers for RBI. The aim of this proof-of concept study is to determine the utility of brain-derived circulating free DNA (BncfDNA), identified by specific methylation patterns for neurons, astrocytes, and oligodendrocytes, as biomarkers brain injury induced by radiotherapy. Methods Twenty-four patients with brain metastases were monitored clinically and radiologically before, during and after brain radiotherapy, and blood for BncfDNA analysis (98 samples) was concurrently collected. Sixteen patients were treated with whole brain radiotherapy and eight patients with stereotactic radiosurgery. Results During follow-up nine RBI events were detected, and all correlated with significant increase in BncfDNA levels compared to baseline. Additionally, resolution of RBI correlated with a decrease in BncfDNA. Changes in BncfDNA were independent of tumor response. Conclusions Elevated BncfDNA levels reflects brain cell injury incurred by radiotherapy. further research is needed to establish BncfDNA as a novel plasma-based biomarker for brain injury induced by radiotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85178498527&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0285646
DO - 10.1371/journal.pone.0285646
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 38015964
AN - SCOPUS:85178498527
SN - 1932-6203
VL - 18
JO - PLoS ONE
JF - PLoS ONE
IS - 11 November
M1 - e0285646
ER -
